Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellyn L Peterson

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Gene Therapy|January 5, 2021
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the <i>mdx</i> Mouse Model of Duchenne Muscular DystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Molecular Therapy. Methods & Clinical Development|February 8, 2024
Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74Rachael A Potter, Ellyn L Peterson, Danielle Griffin, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Gene Therapy|January 5, 2021
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the <i>mdx</i> Mouse Model of Duchenne Muscular DystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Molecular Therapy. Methods & Clinical Development|February 8, 2024
Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74Rachael A Potter, Ellyn L Peterson, Danielle Griffin, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Pageof 1